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‘‘Kind words can be short and easy to speak, but their echoes are truly endless. Every 
time you smile at someone, it is an action of love, a gift to that person, a beautiful thing’’ 







Malaria is a Tropical disease caused by different parasites species of genius Plasmodium. 
Because of pregnancy associated lowered immunity, women who are pregnant are at 
higher risk to malaria infection than non-pregnant women. Malaria infection in pregnancy 
is public health problem particularly in sub-Saharan Africa causing anemia to mothers, 
premature-birth, stillbirth and low birth weights (LBW) .  To minimize the risk of malaria 
and its associated poor outcomes, the World Health Organization (WHO) endorsed 
preventive policy for all pregnant women residing in endemic areas. The policy include 
receiving intermittent preventive treatment in pregnancy (IPTp) with a drug sulfadoxine-
pyrimethemine (SP) each month commencing from early second trimester, owning and 
using insecticide treated bed nets (ITNs) and timely symptomatic malaria case treatment. 
The rapidly growing resistance of malaria-causing organisms (P. falciparum) to SP rises 
questions on the potency of IPTp with SP (IPTp-SP). This activated the exploration of an 
alternative drug for IPTp. In endemic areas with high malaria transmission intensity, IPTp 
with dihydroartemisin-piperaquine (IPTp-DHP) given early during the second trimester 
(≤20 weeks) was reported to be superior to the standard IPTp-SP for protection against 
parasitemia and placental malaria but not negative birth outcomes. However, variability 
in malaria transmission intensity is a crucial factor which could possibly impact the 
outcomes of an intervention. In addition, the association between piperaquine 
pharmacogenetics and pharmacokinetics with IPTp-DHP outcomes were lacking in the 
literature.  
This thesis investigated the effectiveness of the standard monthly IPTp-SP versus IPTp-
DHP for protection of malaria and negative birth outcomes from a setting with moderate 
malaria transmission intensity. We recruited women on their really timing to the first 
ANC, thus pregnant women both on their second and third trimesters were included. 
Firstly, we explored the burden of asymptomatic parasitemia, anemia and associated 
factors among pregnant women attending their first antenatal care (ANC) (Paper I). We 
found that, 36.4% of women had asymptomatic parasitemia associated with anemia at 
their initial ANC. Women who are pregnant for the first time and adolescent were found 
to have higher risk of asymptomatic parasitemia and anemia compared to women who are 
pregnant for more than once and adult, respectively. 
In paper II, we prospectively evaluated the safety and effectiveness of the standard IPTp-
SP for preventing malaria in pregnant women and negative birth outcomes .  We observed 
that, one sixth (16%), one fifth (20.9%), and one fourth (26.5%) of women receiving the 
standard monthly IPTp-SP had parasitemia during pregnancy, any parasitemia at delivery 
and any adverse birth outcomes, respectively. We also found 9.4% of women had 
histopathological placental malaria associated with negative birth outcomes. In addition, 
significant association between three and above doses of monthly IPTp-SP with improved 
birth weight was found as compared to less than three IPTp-SP doses.  
In paper III, the effectiveness of the standard monthly IPTp-SP for prevention of malaria 
and associated negative birth outcomes was compared with monthly IPTp-DHP in a 
randomized controlled trial. From a moderate P. falciparum transmission area, IPTp-DHP 
was found to be superior to IPTp-SP for prevention of symptomatic malaria and 
parasitemia during pregnancy, parasitemia and placental malaria at delivery. In addition, 
this thesis observed the superior impact of IPTp-DHP on birth weight as compared to the 
standard IPTp-SP for the first time. 
Finally, we assessed piperaquine pharmacogenetics and day-7 pharmacokinetics with 
their relevance on IPTp-DHP outcomes (Paper IV). We found Day-7 piperaquine 
concentration increasing significantly after each monthly IPTp-DHP. Women with day-7 
piperaquine concentrations <30ng/mL were found to have significantly higher risk of 
having parasitemia during pregnancy as compared to those with higher concentration 
(≥30ng/mL). Also, carriers of defective CYP2C8 allele were found to have significantly 
lower day 7 piperaquine concentration overtime as compared to wild type.  
In conclusion, Asymptomatic malaria and associated anemia at first ANC visit is 
common in sub-Sahara Africa particularly among primigravida and adolescent pregnant 
women. In addition, we reported considerable burden of parasitemia, placental malaria 
and associated negative birth outcomes among women receiving the standard IPTp-SP. 
This thesis also reaffirmed the role higher doses of IPTp-SP in improving birth weight 
from areas with high P. falciparum resistance to SP. Notably, we reported for the first 
time the superior effect of IPTp-DHP for prevention of malaria in pregnancy and 
improving birth weight as compared to IPTp-SP from a setting with moderate malaria 
transmission intensity. We also reported significant association between lower day-7 
piperaquine concentrations with the risk of malaria during pregnancy.  Lastly, we found 
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1 INTRODUCTION  
1.1 AN OVERVIEW OF MALARIA  
Malaria is a parasitic disease mostly occurring in the tropical and sub-tropical regions and 
caused by the microorganisms belonging to genus Plasmodium. Species of Plasmodium 
known to be important causes of malaria disease in human are currently six [1]. However, 
Plasmodium falciparum is the most common parasite associated with disease morbidity and 
mortalities in sub-Sahara Africa. P. malariae and the two species of P. ovale (P. ovale 
curtisi, P. ovale wallikeri) are less common causes of disease and its consequences. On the 
other hand, P. vivax is the most common specie causing malaria in Latin America and to 
some extent in some parts of Africa and Southeast Asia. In recent years, a zoonotic parasite 
of simian, known as Plasmodium knowlesi appeared to be a key cause of human malaria 
especially in Southeast Asia [2,3].  
Malaria parasites are transmitted to humans by female mosquitoes of the genus Anopheles. 
In Africa, a number of anopheles species are responsible for the transmission of malaria, but 
three species are the most common, namely; An. gambiae, An. arabiensis and An. funestus 
[4]. Among these three primary dominant vector species, An. gambiae and An. funestus tend 
to bite indoor and during the night when people are asleep [4]. On the other hand, An. 
arabiensis easily adopt to drier environments and tend to feed outdoors [4].  
1.1.1 Plasmodium falciparum life cycle 
Plasmodium parasites life cycle alternate between female anopheles mosquitoes and human 
host (Figure 1). Usually, parasites in the stage known as sporozoites are released and 
transmitted to human through the dermis by the mosquito during feeding. From the dermis, 
sporozoites gain access to the blood through cellular traversing [5] and migrates to the liver 
cells within some minutes to few hours [6]. The invasion of sporozoites to hepatocytes is 
facilitated through binding of parasites to hepatocytes surface proteins known as tetraspanin 
CD81 and scavenger receptor B1 (SR-B1) [7]. After 2-10 days since entry, parasites mature 
in the hepatocytes and create parasite filled vesicles well known as merosomes. Merosomes 
protect the parasites against human host immunity and ensures their migration into the red 
blood cells. Merosomes are then released into the liver blood vessels known as sinusoids [8]. 
Then, merosomes rupture and release malaria parasites called merozoites in this stage. 
Merozoites rapidly invade erythrocytes through binding to receptors in human red blood 
cells using parasites’ erythrocyte binding ligands (EBLs) [9]. Within erythrocytes, each 
individual merozoite divides asexually to form a colony of parasites known as schizont. 
After 48 hours since erythrocytes infection, the schizont ruptures, release several merozoites 
(16 to 32) and each merozoite initiate a new infection cycle (Figure 1). Furthermore, the 
rupture of schizont is associated with the clinical symptoms of malaria. Some of the 
parasites in infected red blood cells commit to sexual development where they form male 
and female gametocytes. The maturity of P. falciparum gametocytes occurs in the bone 
marrow and takes about 11 days since commitment has initiated [10]. This stage determines 
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the transmission of parasites to mosquito and is one of the key intervention point through 
transmission blocking medicines or vaccines. When mosquitoes feed on human blood, 
mature gametocytes are taken to the mosquito. Finally, male and female gametocytes fuse in 
mosquito and the cycle begins again (Figure 1). 
 
Figure 1. Representation of Plasmodium falciparum life cycle both in human and in mosquito hosts. 
Adapted with permission form Maier AG. et al. (2018) [11]. 
1.1.2 Immunity against Malaria  
Human immunity against malaria involves both innate and adaptive mechanisms. Innate 
immune reaction responding to malaria infection is a first-line impeding the development of 
malaria parasite and activate defensive immunity via adaptive mechanism. During malaria 
infection, parasite-infected erythrocytes, malaria pigments, merozoites, and complexes 
associated immune are phagocytized by dendritic cells, macrophages and neutrophils [12]. 
This occurs both in hepatocytes and in erythrocytes and modulates immune responses to 
malaria [13]. However, during blood stage infection, when macrophages engulf infected red 
blood cells, malaria pigments and merozoites, they cannot secrete mediators such as 
chemokines and cytokines; thus, they become immunosuppressive and dysfunctional [14,15]. 
Therefore, in this stage dendritic cells have the role to release these mediators reacting to 
malaria parasites, as well as interacting with the adaptive and innate immune mechanisms. 
During pre-erythrocytic stage, cell-mediated immunity with CD8 T cells and neutralizing 
antibodies are involved. The parasites’ surface proteins known as circumsporozoite proteins 
(CSPs) are important target antigens. The primary role of antibodies is to counteract 
sporozoites and inhibit them from infecting liver cells, whereas CD8 T cells initiate 
cytotoxic effects and destroy the parasites [16]. In fact, CSPs are key targets for malaria 
vaccine development. For effective protection against malaria infection, high amount of 
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antibodies against CSPs are required. Unfortunately, a normal infection induces insufficient 
CSP-specific antibodies [17]. In addition, the protection against parasite infection is further 
compromised when the blood cycle begins. In this case, cell-mediated responses in the liver 
is suppressed due to infection in erythrocytes [18]. 
During infection stage in erythrocytes, there is no cytotoxic response because red blood cells 
lack antigen-presenting mechanism [19]. Thus, protection via antibody-mediated mechanism 
is a critical constituent of naturally acquired immunity in this stage. The family of P. 
falciparum erythrocyte membrane proteins (PfEMPs) are the main earmarks of antibodies 
against malaria infection in blood-stage infection [20]. The likely antibody effector 
mechanisms include; increased clearance of infected erythrocytes through antibodies-
antigens reaction, obstructing infection of new red blood cells, or antibody-mediated cellular 
killing [21]. 
After an acute malaria infection antibody titer rapidly decline to low levels. However, adult 
people living in endemic areas usually maintain high antibody levels due to repeated 
episodes of infections [22]. This explains why people living in low-endemic area have poor 
immunity against malaria compared to those living in moderate and high-endemic areas. 
However, this immunity is not a sterilizing type but rather keeps the parasites at low density 
unable to elicit symptoms. At any time when immunity is compromised the parasites 
balanced at low density can multiply and cause symptomatic infection a phenomenon called 
recrudescence. Usually, a term premunition is used to describe the balance between malaria 
infection and human immunity. Premunition is hypothesized to occur as a result of 
interaction between protective antibodies and monocytes leading to production of soluble 
mediators which block the division of intra-erythrocytic parasites at the trophozoite stage 
[21]. This might explain partly why asymptomatic malaria cases are common in endemic 
areas. In addition the immunity acquired with repeated malaria exposure may not protect 
individuals from being re-infected.  
1.2   THE GLOBAL BURDEN OF MALARIA 
Malaria is still a public health problem causing ill health and associated mortalities, 
particularly in resource-limited countries, despite the substantial decline in burden globally. 
The beginning of a new millennium in the year 2000 is particularly important, giving the 
new direction in the fight against malaria globally. The Millennium Development Goals 
(MDGs) brought forth during this year stimulated political support and great financial 
commitments, which led to the rise of new innovative strategies for the control of malaria 
[23]. Indeed, this resulted in substantial achievements in the war against malaria. For 
instance, worldwide, malaria annual incidence and death rate have respectively reduced by 
36% and 60% from the year 2000 to 2016 [24].  
In 2015, the ‘‘Global Development Sustainable Goals’’ (SDGs) came forth to sutain the 
achievements of MDGs. During this year, the World Health Organization (WHO) endorsed 
the special strategy for malaria control known as ‘‘the Global Technical Strategy for 
Malaria 2016–2030 (GTS 2016-2030)’’ [25]. In fact, the GTS 2016-2030 was the special 
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interpretation of the malaria-specific global ‘‘SDG 3.3’’ that aimed to end in addition to 
malaria, the epidemics of acquired immunodeficiency syndrome (AIDS), tuberculosis, and 
neglected tropical diseases (NTDs) by 2030 [26]. The GTS 2016-2030 was introduced to 
sustain the malaria control achievements, aiming to lower further the incidence of malaria 
and malaria-associated death rates by 90% at the end of 2030 compared to the levels of 2015 
[25]. By the end of 2020, the GTS aimed to reduce malaria incidence and mortality rates by 
at least 40% compared with 2015 levels [25]. However, the global annual estimated malaria 
cases increased from 218 million cases in 2015 [27]  to 231 million cases in 2017 [28], 228 
million cases in 2018 [29] and 229 million cases in 2019 [30]. On the other hand, malaria 
related mortality decreased by 10% from 453,000 deaths in 2015 [27] to 405,000 deaths in 
2018 [29] and 409,000 in 2019 [30]. The increase in global malaria burden in the past three 
years suggest that the 2020 targets for GTS 2016-2030 are less likely to be attained. The 
poor progress in malaria reduction might be due to sub-optimal control strategies, financial 
constrains or other social determinants which really need to be addressed.  
Above 90% of global malaria cases and malaria-associated mortality occur in sub-Saharan 
Africa affecting mostly pregnant women and children (Figure 2). In sub-Saharan Africa, 
estimates indicate that, more than 33 million pregnant women are at risk for malaria 
infection [31]. About 11 million and 12 million pregnant women had malaria infection in 
2018 and 2019, respectively [29,30]. Following the stall in the progress for malaria reduction, 
WHO in collaboration with Roll Back Malaria (RBM) program launched a country-specific 
approach in 2018 to help countries with a high burden of malaria to get back to the track 
towards GTS targets [32].  
 




1.3 MALARIA BURDEN IN TANZANIA 
In Tanzania, the transmission of malaria is diverse. Some areas have high transmission 
intensity while others have moderate, low malaria and very low transmission intensities 
(Figure 3). Zones of high transmission intensity are found on the northwest and southern 
part of the country. The zone of moderate transmission is located on the coastal area, 
whereas low and very low transmission intensity are found on the middle and north eastern 
part of the country. Tanzania is currently listed as one of the 11 high malaria burden 
countries and contributed more than 6 million cases of the global malaria burden in 2018 
and 2019 [29,30]. Nevertheless, the malaria burden in Tanzania decreased substantially 
within three years from 2014 (15%) [34] to 2017 (7.3%) [35]. The substantial reduction of 
malaria burden has been contributed by the optimization of malaria control strategies. This 
finding could suggest that Tanzania is making good progress towards malaria elimination. 
However, the WHO estimated an increase in malaria cases from Tanzania in 2018 and the 
same estimate was reported in 2019 [29,30], indicating a turning back. Equally, the 
proportion of pregnant women testing positive during ANC visit only decreased by 1.4% 
between 2014 to 2018 [36]. In 2010, a mathematical model estimated that, about 500,000 
pregnant women in Tanzania are exposed to malaria infection [37]. Persistent malaria among 
pregnant women despite the decline in the general population may indicate the requirement 
for additional control approaches among pregnant women.  
 
Figure 3. Tanzania map showing the pprevalence of malaria among children under five years of age 




1.4 MALARIA IN PREGNANCY 
Pregnant women have increased risk of malaria infection than women who are not pregnant. 
Usually, adults from endemic areas have acquired immunity to malaria due to prior 
exposure over the life course. However, the high probability of malaria infection in women 
during pregnancy might be explained by two mechanisms. The first mechanism involves 
immune modulation which occurs during pregnancy. Usually, during pregnancy cortisol 
hormone levels are increased while the levels of prolactin hormone decrease. The increased 
cortisol hormone and the decreased prolactin hormone cause non-specific 
immunosuppression [38-40]. Additionally, there is temporary impairment of cell mediated 
immune to support the development of placenta and the growing fetus [41]. Since cell 
mediated immune mechanisms are crucial in malaria protection, their suppression during 
pregnancy partly explains the vulnerability of pregnant women to malaria [42]. The 
preferential accumulation of infected erythrocytes to the placenta is the second mechanism 
for the high risk of malaria during pregnancy.  
In moderate and high endemic areas, primigravida women have increased chances of 
malaria infection, severity and malaria associated poor birth outcomes than multigravida  
[43]. On the contrary, in low-endemic areas, because of low acquired immunity, all pregnant 
women regardless of parity are equally susceptible to malaria and malaria associated 
adverse birth outcomes. The increased susceptibility among primigravida in moderate to 
high transmission areas is due to low placental parasite specific immunity [44] which is 
parity dependent and protects pregnant women in the subsequent pregnancies [45].  
1.4.1 The pathogenesis of Placental Malaria 
Malaria associated adverse birth outcomes occur due to accumulation of malaria infected 
erythrocytes to the placenta. In pregnant women, P. falciparum malaria parasites express 
unique variant gene (var2csa) which codes for unique adhesive variant antigens on the 
surface of infected red blood cells [46]. These adhesive molecules are part of PfEMP1family 
specifically binding to chondroitin sulfate A and mediate the accumulation of malaria 
infected erythrocytes to the placenta. These var2csa proteins are the main targets for vaccine 
development against placental malaria [47]. The accumulation of infected erythrocytes to the 
placenta, causes inflammatory response [48]. The placental inflammation result in 
histological changes including the deposition of malaria pigment, penetration of 
mononuclear cells, complement deposition, the trophoblast basement membrane thickening 
and syncytial knotting [49-51]. Placental histological changes lead to changes in placental 
angiogenesis which causes changes in the architecture of placental villous [52] and surface 
area for nutrient transfer [53-55]. In turn, utero-placental blood flow is impaired, leading to 
insufficiency nutrient transport across the placenta, causing intrauterine growth restriction 




Figure 4. Scheme representing the pathogenesis of placental malaria. Abbreviations: CSA, 
chondroitin sulfate A; C5a, complement component 5a; PEs, parasitized erythrocytes; sFlt-1, soluble 
fms-like tyrosine kinase-1. Adapted from Conroy AL. et al. (2019) [58]. 
1.4.2 Maternal effects associated with Malaria in Pregnancy 
Infection with malaria during pregnancy causes maternal illness associated with malaria 
fever, chills, and general body weakness. On rare occasions, severe malaria during 
pregnancy may occur and is usually associated with organ damages and a high risk of 
maternal mortality [59,60]. In sub-Saharan Africa, malaria in pregnancy is the main 
contributor of maternal anemia. Maternal anemia during pregnancy is an indirect cause of 
malaria-associated maternal death [61]. Plasmodium falciparum causes anemia by various 
mechanisms including hemolysis, increased splenic clearance of both infected and non-
infected erythrocytes, and reduced erythrocytes production [62,63].  
On the other hand, a study from Malawi estimated that, a single malaria episode may cost 
beyond a week’s worth of income for families as direct and indirect economic effects [64]. 
Since women largely contribute to the family income, malaria in pregnancy may impose 
most families and communities in sub-Saharan Africa to the poverty cycle.  
1.4.3 Fetal effects associated with Malaria in Pregnancy  
Malaria-associated fetal growth restriction increases the risk of having LBW new-born. The 
risk of malaria-associated LBW increase when the infection is repeated during pregnancy 
[65]. In addition, the risk of having LBW is higher for women with placental infection 
compared to women with only peripheral blood parasitemia [66]. More than 800,000 LBW 
infants in sub-Saharan Africa were associated with malaria exposure during pregnancy in 
2018 and 2019 [29,30]. The model estimates that infants born with LBW have a three-fold 
risk of mortality than infants born with normal birth weight [67,68]. Moreover, LBW infants 
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have a high risk of poor neurodevelopment and lower Intelligence quotient (IQ) compared 
to infants born with normal birth weight [69]. 
On the other hand, malaria in pregnancy is one of the substantial causes of stillbirth in 
Africa. Essentially, the risk of malaria-associated stillbirth is twice higher in low to 
moderate endemic areas compared to high endemic areas [70]. A systematic review 
estimates that, about 12-20% of stillbirths occurring in sub-Saharan Africa are attributed to 
malaria in pregnancy [70]. Additionally, malaria in pregnancy is also associated with preterm 
birth. In East Africa, a systematic review reported that pregnant women infected with 
malaria are three times more likely to have preterm birth than pregnant women without 
malaria [71].  
1.4.4 Infants’ effects associated with Malaria in Pregnancy 
Maternal malaria infection may be the cause of congenital malaria [72] and early malaria 
infection in infants [73,74]. The association of malaria in pregnancy and the increased risk of 
infancy malaria may be explained by two hypotheses. Firstly, histological changes 
happening during placental infection may interfere with the passage of maternal antibodies 
to the offspring [75]. This may result in a compromised fetus and infants’ immunity, thus 
increasing the risk of malaria infections in early childhood. Secondly, when the fetus is 
exposed to malaria in utero, it induces the development of regulatory T-cells (Treg), which 
cause tolerance of fetal immunity to malaria antigens that persevere to infancy [76]. 
Additionally, malaria in pregnancy increases the risk of infant anemia [77]. On the other 
hand, exposure to malaria in pregnancy was associated with less height and weight gain 
during the first year of life [78,79]. 
1.5 PREVENTION OF MALARIA IN PREGNANCY 
To minimize the susceptibility of malaria among pregnant women, the WHO approved a 
package of preventive strategies among pregnant women residing in endemic areas. The 
package consists of ‘‘timely diagnosis and effective treatment of symptomatic malaria, 
intermittent preventive therapy during pregnancy (IPTp) with a drug sulfadoxine-
pyrimethamine (SP), utilization of bed nets treated with insecticide (ITNs) and spraying 
indoor residuals’’ [80]. A systematic review of data from 32 countries in Africa indicated 
that the use of malaria prevention strategies significantly reduced LBW and infant mortality 
[81]. These strategies have been adopted and implemented by endemic countries in Africa 
including Tanzania [82].  
1.5.1 Insecticide treated bed nets and residual spraying 
Bed nets impregnated with the long-lasting insecticide, commonly pyrethroids, are known 
as insecticide-treated bed nets (ITNs). The recommendation for using ITNs as an extensive 
control strategy for prevention of malaria came forth in 1999 [30]. In the year 2000, the 
WHO approved the first long lasting ITNs for malaria prevention [30].  Currently, ITNs are 
extensively implemented for the control of malaria in endemic areas largely in Africa. 
 
 9 
Between 2000 and 2015, the use of ITNs have prevented 68% of malaria cases in Africa 
[83]. Systematic review estimate that, the use of ITNs in pregnancy substantially reduce the 
risk of LBW, miscarriages, stillbirths and placental parasitemia [84,85]. Despite the 
demonstrated efficacy of ITNs in sub-Saharan Africa, there is slow coverage of INTs. For 
instance, the overall coverage of INTs was 61% in 2018 [29], similar  to the coverage in 
2015 [27]. In 2019, the estimated coverage of ITNs ownership in sub-Saharan Africa was 
68% [30]. 
In Tanzania, according to malaria control policy, all pregnant women receive ITNs through 
antenatal care (ANC) and expanded program for immunization [86]. The coverage of ITNs 
ownership increased to 78% in 2018 [87]. However, low utilization of ITNs among pregnant 
women could be a challenge for malaria control among pregnant women. For instance, 
according to the national malaria indicator survey, the utilization of ITNs among pregnant 
women in Tanzania has droped from 75% in 2010 to 51% in 2017% [34,35]. On the other 
hand, a systematic review reported a rapid increase in mosquitoes’ resistance to insecticides 
in Tanzania which threats the future performance of INTs [88]. Similarly, an increase in 
mosquitoes’ resistance to insecticides has been reported from other countries in Africa [89]. 
A recent WHO recommendation indicates that bed nets may be treated with both 
pyrethroids and an added synergist insecticides like piperonyl butoxide in areas with 
reported mosquito resistance to pyrethroids [90].  
1.5.2 Intermittent preventive treatment in pregnancy with sulfadoxine-pyrimethamine 
(IPTp-SP) 
1.5.2.1 Sulfadoxine-pyrimethamine (SP) and its mechanism of action 
Due to widespread resistance of P. falciparum, SP was removed as the treatment regimen 
and restricted for IPTp. SP act through the inhibition of enzymes which catalyze crucial 
consecutive steps in the synthesis of folate products. Sulfadoxine is an analogue of p-amino 
benzoic acid which inhibit dihydropteroate synthase (DHPS) enzyme, a crucial step in the 
parasites’ folate synthesis [91]. On the other hand, pyrimethamine inhibit competitively 
dihydrofolate reductase (DHFR) a key enzyme for the production of tetrahydrofolate, which 
is an important cofactor required in the biosynthesis of parasites nucleotides and proteins 
[92]. The fact that Mammalian cells acquire folate derivatives from dietary intake as they 
don’t synthesize folates de novo, explain the selective activity of SP. Inhibition of DHPS 
and DHFR is synergistically important, leading to depletion of the important cofactors, 
which interrupts the synthesis of nucleotides and proteins, thus killing the parasite. 
1.5.2.2 The IPTp-SP policy 
In the year 1998, the WHO recommended IPTp as one of the control strategies for 
prevention of malaria during pregnancy [30]. IPTp-SP involves the administration of a single 
dose of SP at each monthly ANC beginning early second trimester till delivery. The IPTp 
policy changed overtime depending of research based evidence. Currently, according to the 
WHO policy, three and above doses of IPTp-SP given at least one-month interval are 
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considered as an optimal coverage [93]. Since the change of IPTp-SP policy to three and 
above as an optimal strategy, its coverage increased rapidly to 31% in 2015 [27]. 
Conversely, the uptake of optimal IPTp-SP (≥3 SP) in sub-Saharan Africa has slowed down 
since 2015. For instance, in 2017, the coverage of three and above doses of IPTp-SP in sub-
Saharan Africa was 26% [28] and increased to 31% in 2018 [29], which was similar to the 
coverage in 2015 [27]. In 2019, the optimal IPTp-SP coverage increased to 34% [30]. 
A systematic review indicated that most countries in sub-Saharan Africa are far away from 
the 80% target coverage of optimal IPTp-SP [94]. Besides, studies reported different 
coverages from different countries in sub-Saharan Africa. For instance, a study from Ghana 
reported 63% coverage of optimal IPTp-SP [95]. In Benin, a study reported that 34% of 
pregnant women received optimal IPTp-SP [96]. The coverage of optimal IPTp-SP in 
Tanzania was 26% in 2017 according to malaria indicator survey [35].  
Evidence from the literature indicates that optimal IPTp-SP (three and above SP doses) 
improve birth weight [97-100]. A previous study reported no association between optimal 
IPTp-SP and LBW [101]. On the other hand, the efficacy of optimal IPTp-SP (three and 
above SP doses) on malaria in pregnancy is controversial. While some studies indicate that 
receiving three and above doses of IPTp-SP is associated with protective effect on malaria 
in pregnancy [102,103],  others reported that three and above doses of IPTp-SP does not 
protect malaria in pregnancy more than the lower doses of IPTp-SP [104-106]. The limited 
and inconsistent data on the efficacy of IPTp-SP, suggest the need to evaluate its 
performance regularly in order to provide updated information.  
1.5.3 Effective malaria case management 
Effective malaria case diagnosis and treatment during pregnancy is one of the malaria 
control strategies implemented. Usually, malaria rapid diagnostic test (mRDTs) and 
microscopy are used for routine diagnosis of malaria in sub-Saharan Africa. Symptomatic 
cases of malaria in pregnancy can be easily diagnosed using the standard methods and 
treated. Artemisinin-based combination therapies (ACTs) are used to treat uncomplicated 
malaria from the second trimester while oral quinine plus clindamycin are used during the 
first trimester as recommended by the WHO [107]. However, recent evidence suggests that 
ACTs could be safe for treating uncomplicated malaria in the first trimester [108]. ACTs 
have demonstrated high cure rates for the treatment of malaria during pregnancy [109]. 
Immediate treatment of malaria prevents chronic placental malaria and improves birth 
outcomes [110].  
Nevertheless, most cases of malaria in pregnancy are asymptomatic. In asymptomatic 
malaria, there is usually low parasite density, thus most cases may be missed by the routine 
methods, microscopy, and mRDTs due to their limited sensitivity [111]. Therefore, 
asymptomatic malaria in pregnancy may remain untreated and cause adverse birth 
outcomes. On the other hand, asymptomatic malaria in pregnancy may serve as pool 
facilitating malaria transmission in endemic countries. A modeling analysis estimated that, 
in a non-pregnant population where 90% of people received mass drug administration for 
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malaria control, pregnant women may possibly contribute up to 23·9% of the new infections 
in the population [112]. In fact, the WHO has acknowledged asymptomatic malaria as one of 
the obstacles for successful control of malaria and requires control approaches to address 
asymptomatic malaria, especially in pregnant women [25]. However, for effective designing, 
planning and strengthening strategies for the control of asymptomatic malaria, data on the 
burden of asymptomatic malaria in pregnancy are needed. In sub-Saharan Africa, the burden 
of asymptomatic malaria in pregnancy could be high, but data are scarce. For instance, 35%, 
50%, and 54% of pregnant women were found to have asymptomatic malaria at first ANC 
visit in Kenya, Uganda, and Malawi, respectively [113-115]. Given the limited data on the 
burden of asymptomatic malaria in sub-Saharan African countries, including Tanzania, 
research is needed to inform policy makers. 
1.6 P. FALCIPARUM RESISTANCE TO SP AS A CHALLENGE FOR 
PREVENTION OF MALARIA IN PREGNANCY 
Tracking of SP resistance is done through monitoring the key mutations in P. falciparum 
dihydrofolate reductase (Pfdhfr) and dihydropteroate synthetase (Pfdhps) genes. Various 
single nucleotide polymorphisms haplotypes in the Pfdhps and Pfdhfr genes cause P. 
falciparum resistance to sulfadoxine and pyrimethamine, respectively. Three mutations in 
Pfdhfr (N51I, C59R and S108N) and two mutations in Pfdhps (A437G and K540E), 
together form the quintuple haplotype. Quintuple haplotype is associated with high P. 
falciparum resistance to SP in East Africa [116,117]. An extra mutation (A581G) in the 
Pfdhps genes resulted in a highly resistant combination known as sextuple haplotype [118]. 
To evaluate the effect of SP resistance on the efficacy of IPTp-SP, the prevalence of Pfdhps 
K540E and Pfdhps A581G within the population represent quintuple and sextuple 
haplotypes, respectively.  
In sub-Saharan Africa, the increasing prevalence of P. falciparum resistance to SP poses 
threats to the efficiency of IPTp-SP. In a multi-country study, the efficiency of SP to clear 
existing parasitemia and protect pregnant women against new malaria infections was found 
to decrease with the increasing prevalence of Pfdhps K540E mutation [119]. Equally, the 
effectiveness of IPTp-SP to prevent LBW was found to be lower in areas with a high 
population prevalence of Pfdhps K540E mutation [120]. The sub-optimal activity of SP to 
clear parasites may be one of the reasons for sustainable malaria transmission in sub-
Saharan Africa. This might be explained by the fact that asexual parasites not cleared by SP 
could differentiate into sexual forms and increase peripheral gametocytemia [121], which are 
the transmittable stages of P. falciparum to the mosquito. In fact, some studies have 
reported that women who received IPTp-SP had significantly higher gametocytemia at 
delivery than those who did not receive IPTp-SP [122,123].  
On the other hand, a systematic review reported that 10% population prevalence of Pfdhps 
A581G mutation could indicate the boundary for IPTp-SP efficacy above which it is no 
longer effective [124]. The WHO suggests stopping IPTp-SP in areas where the population 
prevalence of Pfdhps K540E mutation is greater than 95%, and the prevalence of Pfdhps 
A581G mutation is greater than 10%, since the efficacy of IPTp-SP is likely to be lost [93].  
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Various studies have reported diminishing efficacy of IPTp-SP in areas with a higher 
prevalence of A581G mutation. For example, a study from an area where the prevalence of 
Pfdhps A581G is 36% in Uganda reported that IPTp-SP efficacy on malaria and LBW was 
not found [125]. Similarly, studies from northeast Tanzania, where the prevalence of Pfdhps 
A581G mutation is high [126], reported loss of IPTp-SP efficacy [101,127]. Eventhough  the 
population prevalence of Pfdhps A581G mutation is below 10%, infection with parasites 
harbouring Pfdhps A581G are associated with significantly lower birth weights among 
pregnant women receiving IPTp-SP [128]. Besides, a study from the Democratic Republic of 
Congo reported 47% population prevalence of A581G [129]. Similarly, the prevalence of 
Pfdhps K540E in Tanzania is 90.4% [130]  close to saturation (>95%).  Given the adverse 
effects of malaria during pregnancy and the increasing resistance of P. falciparum to SP, 
there is an urgent need to explore alternative strategies for effective control of malaria 
among pregnant women. 
1.7 ALTERNATIVE STRATEGIES EVALUATED FOR PREVENTION OF 
MALARIA IN PREGNANCY IN SUB-SAHARAN AFRICA 
In sub-Saharan Africa, extensive P. falciparum resistance to SP compelled the need for 
alternative strategies to prevent malaria in pregnancy. Various antimalarial drug regimens 
were assessed in the search for an alternative regimen for IPTp. In Ghana, amodiaquine or 
addition of amodiaquine to SP for IPTp was investigated against the standard IPTp-SP [131]. 
However, IPTp with amodiaquine or amodiaquine-SP was not tolerated and was not 
superior to the standard IPTp-SP. Similarly, a multicentre study reported that mefloquine 
was poorly tolerated and failed to replace SP for IPTp [132]. In addition, a combination of 
azithromycin and chloroquine evaluated in a multicentre study was less tolerated and did not 
have superior effects to the standard IPTp-SP [133]. On the other hand, an addition of two 
doses of azithromycin to monthly IPTp-SP in Malawi was found to improve birth weight 
[134] but not superior to IPTp-SP for malaria prevention [135]. Artemisinin-based 
combination therapies (ACTs) were used in studies to evaluate intermittent screening and 
treatment of asymptomatic pregnant women (ISTp)   during ANC visits as an alternative 
strategy. However, results regarding the efficiency of ISTp are contradicting.  Essentially, a 
multicentre study in west Africa reported that ISTp using artemether-lumefantrine (AL) was 
non-inferior to IPTp-SP [136]. On the contrary, a trial in Nigeria reported that ISTp-AL was 
superior to IPTp-SP [137]. On the other hand, two studies in high malaria transmission areas 
consistently reported that ISTp was inferior compared to IPTp-SP. One study from Malawi 
reported that ISTp using dihydroartemisinin-piperaquine (DHP) was significantly associated 
with a high prevalence of malaria at delivery than IPTp-SP [115]. Similar findings were 
reported by a trial done in Kenya [113]. Another multicentre trial in West Africa investigated 
whether adding regular screening and treatment of malaria with AL in the community to the 
IPTp-SP would improve maternal and infant health [138]. However, this approach did not 
reduce malaria in pregnancy significantly as compared to IPTp-SP alone. Based on the 
limited sensitivity of malaria rapid diagnostic tests currently used, the WHO concluded that 
ISTp should not be an alternative choice [139]. 
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1.7.1 Optimization of artemisinin-based combination therapy (ACT) for prevention 
of malaria in pregnancy 
In sub-Saharan Africa, ACTs are the first-line regimens for the treatment of malaria since 
2004 [107]. The safety and efficacy of ACTs for treating uncomplicated malaria from the 
second trimester is well established [140-142]. However, the fact that most malaria cases 
during pregnancy do not present with clinical symptoms warrant the need to further explore 
ACTs as alternative regimens for IPTp. This need is supported by the malaria GTS 2016-
2030 which recommends the optimization of existing strategies towards malaria elimination 
[25]. Among the available ACTs, DHP provides the most favourable features for this 
treatment approach. The combination of DHP is given once a day, therefore less compliance 
problems compared to other ACTs with more than once dosing per day. DHP is also well-
tolerated, with the longest half-life providing sufficient post-treatment malaria prevention 
[143] which is needed for the IPTp regimen.  
In east Africa, trials indicated that the combination of DHP could serve as an alternative 
regimen to SP for IPTp. A trial in Kenya evaluated IPTp with DHP versus the standard 
IPTp-SP and reported a significant reduction in parasitemia and malaria outcomes 
associated with IPTp-DHP when compared with the standard IPTp-SP [113]. Similarly, a 
trial from Uganda reported significant protection against malaria and parasitemia during 
pregnancy associated with IPTp-DHP compared to IPTp-SP [114]. Another trial from 
Uganda reported the safety of IPTp-DH given monthly and superior effects on parasitemia 
and placental malaria but not on negative birth outcomes [144]. However, the trials from 
Uganda included pregnant women with gestation ages between 16 to 20 weeks. In addition, 
the trials were conducted in areas with high malaria transmission intensities. Similarly, the 
trial from Kenya was done in a setting with high malaria transmission but compared three 
doses of IPTp-DHP or monthly IPTp-DHP versus IPTp-SP in women on their second and 
third trimesters. Bearing the influence of malaria transmission intensity on the impact of 
IPTp, it was not known whether the findings could be generalized to areas of moderate 
malaria transmission intensities. Furthermore, gestational age below 20 weeks is usually 
earlier than the really gestational ages at first ANC visits in most sub-Saharan African 
countries, including Tanzania. Therefore, more research was needed to be done in real-
world settings and from geographical areas with moderate malaria transmission intensity in 
order to give more evidence [145].  
1.8 THE PROPOSED DHP MECHANISM OF ACTION  
The potent short-acting dihydroartemisinin ensures quick reduction in parasite population, 
leaving low parasite density. The long-acting piperaquine ensures sustained removal of the 
remained parasites and provide prophylaxis against new infection. The anti-malarial 
mechanism of action for dihydroartemisinin is hypothesized to be exerted by its 
endoperoxide bridge. The endoperoxide-bridge causes free-radicals which damage the 
parasite membrane systems through alkylating and oxidizing proteins and lipids in 
parasitized erythrocytes leading to parasite death [146,147]. On the other hand, the exact 
mechanism of action for piperaquine is not known. It is postulated that piperaquine works in 
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a similar mechanism like chloroquine where it accumulates in the digestive vacuole of 
matured asexual blood-stage trophozoites and inhibit haem-digestion. Normally, parasites in 
red blood cells obtain nutrients by breaking down hemoglobin into amino acids [148]. 
During this process, toxic by-products known as haematin is produced [149]. The parasite 
has a mechanism to detoxify haematin through polymerization to form non-toxic crystal 
structures known as hemozoin or malaria pigment [150]. Thus, the binding of piperaquine in 
heme hinders the polymerization resulting in the accumulation of toxic haematin, which 
destroys the parasite [147,151]. 
1.9 PIPERAQUINE PHARMACOGENETICS AND PHARMACOKINETICS 
The physiological alterations which occur in pregnancy could affect the pharmacokinetics of 
various drugs in different ways [152]. For instance, increased levels of cortisol and estrogen 
hormones during pregnancy are associated with increased expression of drug-metabolizing 
enzymes and transport proteins [153] which could affect drug absorption and clearance. In 
addition, increased body fluids might affect drug volume of distribution. However, most 
studies reported that pregnancy could not  significantly affect the overall exposure of 
piperaquine plasma level [154-156] when used for the treatment of uncomplicated malaria. 
On the other hand, some studies observed a decrease in piperaquine terminal elimination 
half-life but not the overall piperaquine exposure in pregnant women compared to non-
pregnant counterparts [155,157]. The pregnancy-associated reduced terminal elimination half-
life might affect the malaria prophylactic effect of DHP especially when used for IPTp. 
Nevertheless, the impact of piperaquine pharmacokinetics on the treatment outcomes during 
IPTp with DHP was not investigated. 
Evaluating piperaquine pharmacokinetics in the context of IPTp is important for dosing 
optimization.  Few studies have reported the pharmacokinetics of piperaquine in IPTp 
regimen. One study from Uganda conducted during IPTp with DHP, estimated the trough 
plasma piperaquine concentration of 10.3 ng/mL and 13.9 ng/mL to provided 95% and 99% 
protection against malaria, respectively [158]. Based on these targets, a recent study reported 
that, more than 90% of women who received IPTp-DHP in Kenya and Indonesia have 
attained the target trough concentration (10.3 ng/mL) after three doses of monthly IPTp-
DHP [159]. Another study reported 72% higher piperaquine clearance in pregnant women 
than postpartum women [157]. For antimalarial drugs with a long elimination half-life, the 
plasma concentration at day 7 is well correlated with the area under the concentration curve 
(AUC) and could be used to monitor treatment efficacy [160]. In IPTp regimen, data 
regarding day-7 piperaquine pharmacokinetics are not available in the literature. It was 
therefore not known whether day-7 piperaquine concentration could also be used to evaluate 
the effectiveness of IPTp with DHP. 
On the other hand, pharmacogenetic variations could significantly affect the 
pharmacokinetic exposure of anti-malaria drugs. Single nucleotide polymorphism occurring 
on genes coding for drug-metabolizing and transporter proteins could reduce, increase or 
diminish metabolism of drugs [161]. Despite this fact, the influence of genetic polymorphism 
on piperaquine is not well understood. One study evaluated the effect of pharmacogenetics 
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on piperaquine pharmacokinetics in a small sample size for the treatment of uncomplicated 
malaria in Cambodia reported no significant effects [162]. However, different ethnic groups 
have different distributions of gene alleles coding for CYP enzymes. In addition, there are 
no data on the effects of pharmacogenetics on plasma piperaquine level when used for IPTp. 
Given the proven superior malaria protective effect of IPTp-DHP compared to IPTp-SP, 
data of pharmacogenetics on piperaquine plasma concentration in IPTp is importantly 




2 AIMS OF THE RESEARCH  
2.1 GENERAL OBJECTIVE 
Generally, the PhD project aimed at optimizing the intermittent preventive therapy for 
prevention of malaria and negative birth outcomes among HIV uninfected pregnant 
women in Tanzania. The focus was to provide an insight on the burden of asymptomatic 
parasitemia before initiating IPTp, evaluate the effectiveness of monthly IPTp-DHP as 
compared to the current standard of care (IPTp-SP), and to explore the pharmacogenetics 
and pharmacokinetics of piperaquine in relation to treatment outcome during IPTp.  
2.2 SPECIFIC OBJECTIVES 
Paper I To investigate the prevalence and correlates of asymptomatic malaria and anemia 
at the first antenatal care visit before initiating IPTp among HIV uninfected pregnant 
women in Tanzania. 
Paper II To evaluate the effectiveness of the current standard of care (IPTp-SP) for 
prevention of malaria during pregnancy and adverse birth outcomes among HIV 
uninfected pregnant women in Tanzania.  
Paper III To compare the effectiveness of IPTp-DHP versus the standard IPTp-SP for 
prevention of malaria in pregnancy and adverse birth outcomes among HIV uninfected 
pregnant women in Tanzania.  
Paper IV To explore the pharmacogenetics and day 7 pharmacokinetics of piperaquine 
component in DHP, and their relevance on treatment outcome among HIV uninfected 




3 METHODOLOGICAL CONSIDERATIONS  
3.1 STUDY DESIGN AND TARGET POPULATION  
As shown in Figure 5, all four sub-studies targeted pregnant women at their first ANC 
visit. Sub-study one used cross-sectional design (Paper I). For sub-study three (Paper 
III), we used a superiority randomized controlled trial design. Sub-study two (Paper II) 
was a prospective observational study nested in the randomized controlled trial. Similarly, 
sub-study four (Paper IV) was a nested pharmacogenetics and pharmacokinetics study in 
a randomized controlled trial.  
A set of inclusion and exclusion criteria were used for each respective sub-study. We 
determined trimester at enrollment by using the last Menstrual Period, and fundal height 
according to the national standard ANC guidelines [163]. Paper I included pregnant 
women both on their first, second and third trimesters. On the other hand, Papers II, III 
and IV included pregnant women only on their second and third trimesters. This is 
because the study drugs used for IPTp (Papers II and III) are only recommended to 
commence from the second trimester onwards [107].  At enrollment, participants were 
screened for malaria using mRDT and PCR. For paper I, both pregnant women with 
asymptomatic malaria and malaria-free were included. On the other hand, women with 
patent malaria (detected by mRDT) were excluded for Papers II, III and IV. We excluded 
pregnant women with patent malaria because they received treatment with a drug other 
than the study drugs (artemether-lumefantrine), which could affect the study outcomes. In 
the four studies, we excluded pregnant women with a history of malaria and treatment for 
the past one month. This is because the tests we used to screen for malaria (mRDT) at 
enrollment could still give false-positive results within the period of one month since the 
diagnosis as they depend on antigen-antibody reaction. HIV-infected women were also 





Figure 5. Summary of the participants’ population recruited for all the four sub-studies. 
3.2 PARTICIPANT RECRUITMENT AND BASELINE DATA COLLECTION 
PROCEDURES 
In all four sub-studies, we used standard Case Report Forms (CRF) for data collection. 
We collected information regarding sociodemographic, gravidity, parity, gestational age, 
ITN use, medication use, maternal age, and level of education at enrollment in order to 
assess their impacts on our study outcomes. Following standard procedures, weight and 
height were measured using a digital weighing scale in kilograms (nearest 0.1kg) and a 
potable wooden scale in centimeters (nearest 0.1cm), respectively. Body temperature was 
determined from the maternal armpit using a digital thermometer and expressed in degree 
Celsius (ͦ C). A temperature of ≥37.5 ͦ C was considered as fever.  
3.3 RANDOMIZATION AND ADMINISTRATION OF STUDY DRUGS  
For paper III, participants were randomly assigned (1:1) allocation to receive either 
IPTp-DHP or IPTp-SP using a computer-generated randomization list. Opaque, sealed, 
and sequentially numbered envelopes with blind treatment allocations were used to assign 
pregnant women to their respective study groups. In order to ensure adherence to 
allocations, we monitored regularly the sequential arrangement of envelopes. Participants 
in IPTp-DHP arm received a dose of three tablets containing dihydroartemisinin-
piperaquine fixed combination (D-ARTEPP, Guilin Pharmaceutical Co. Ltd, China) once 
daily for three consecutive days. Each tablet contained 40 mg of dihydroartemisinin and 
320 mg of piperaquine. The first dose was given as directly observed therapy (DOT) at 
the ANC. The remaining second and third doses were taken at home 24th and 48th hours 
after the first dose, respectively.  
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On the other hand, women in the standard group (IPTp-SP) received a single dose of three 
tablets, and each tablet contained 500 mg of sulfadoxine and 25 mg of pyrimethamine 
(Orodar, Elys Chemical Industries Ltd, Kenya) as DOT at the ANC. The Tanzania 
National Malaria Control Programme supplied SP tablets through the Medical Stores 
Department. In addition, all participants received mebendazole 500mg and a fixed 
combination containing ferrous sulphate (150mg) plus folic acid 0.5mg once daily for 
prevention of anemia during pregnancy according to ANC guidelines [163]. Tablets with 
folic acid more than 1.5mg were not supplied to the study participants because they might 
interfere with the IPTp-SP malaria protection effect [164,165]. 
3.4 PARTICIPANTS FOLLOW UP PROCEDURES 
Participants in sub-study two, three, and four were scheduled monthly for follow-up visits 
and screened for malaria and anemia. In addition, they received their respective drugs on 
each monthly ANC visits until delivery.  Women who visited study health facility out of 
their scheduled visits were screened for malaria and fever by the study clinicians. 
Furthermore, all participants were assessed on ITNs use at each scheduled ANC visit and 
followed till delivery. 
For sub-study two and three, we recorded adverse birth outcomes from participants and 
newborns. To assess for low birth weight, study midwives weighed newborn babies on a 
digital scale and measured their weight to the nearest 10 g immediately after birth. Birth 
weights below 2500g was considered as LBW. In addition, study midwives examined 
newborn babies for congenital malformation within the first 24 hours of delivery. Also, 
we recorded any miscarriages (occurring below 27 weeks gestational age), still births 
(occurring ≥28 weeks gestational age), premature birth (occurring <37 weeks gestational 
age), and neonatal or maternal deaths. After delivery, we followed participants up to six 
weeks for the purpose of monitoring any congenital anomalies, maternal or neonatal 
deaths within that period. 
3.5 PARTICIPANTS’ MATERIALS AND BLOOD SAMPLE COLLECTION  
We collected blood samples and placental tissue  to evaluate the study outcomes. Blood 
samples were collected using standard routine procedures by experienced laboratory 
technicians. At enrollment, we collected 2ml of venous blood from participants on the 
IPTp-DHP arm for pharmacogenetics study (Paper IV). Similarly, pregnant women who 
received IPTp-DHP had a scheduled visit at day 7 after each monthly administration of 
study drugs, where 3ml of blood was collected for piperaquine pharmacokinetics (Paper 
IV). The whole blood was immediately centrifuged at 2000  g for 10 minutes to obtain 
plasma. The obtained palsma was aliquoted into plastic cryo-vial and stored at -80 oC.  
We used plastic cryo-vial because piperaquine could readily adsorb to glass tubes due to 
its multiple nitrogen atoms and concsequently affect the plasma concentration. Moreover, 
we used day 7 single sampling for pharmacokinetics because it is well correlated with the 
area under the plasma concentration curve (AUC) and it is recommended for monitoring 
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the efficacy of antimalarial drugs with a long elimination half-life, including piperaquine 
[166].  
During each scheduled monthly ANC visit, peripheral finger-prick blood was collected 
for determination of hemoglobin concentration and parasitemia using mRDT and PCR 
(Papers II, III and IV).  
At delivery, blood samples were collected for assessing malaria and anemia outcomes 
(Papers II, III and IV). Maternal venous blood, placental blood, and cord blood were 
collected in EDTA tubes for malaria screening. For further screening of malaria using 
PCR, we collected dried blood samples (DBS) in Whatman filter paper (Whatman, Inc. 
NJ, USA) from finger prick at enrollment and at each scheduled ANC visit and from 
maternal venous blood, cord blood and placental blood at delivery. To detect 
histopathological placental malaria for sub-studies II, III and IV, a section of placenta 
biopsy (approximately 2 cm3) was collected from the maternal side and fixed in 10% 
buffered formalin. 
3.6 DIAGNOSIS OF ANEMIA 
Maternal anemia was monitored as a secondary outcome for sub-studies I, II and III 
whereas fetal anemia was a secondary outcome for sub-studies II and III. We determined 
Hemoglobin concentration from cord blood (fetal anemia) and maternal blood (maternal 
anemia). To determine anemia, we measured Hb concentration (g/dl) using a digital 
HemoCue Hb 201+ analyzer (HemoCue AB, Angelholm, Sweden). Briefly, a drop of 
blood was placed on the test strip, and the strip was inserted into the digital machine for 
reading. Maternal anemia was confirmed when maternal Hb was <11g/dL. Anemia 
severity was defined as Mild (10–10.9 g/dL), moderate (7–9.9 g/dL), and severe (<7 
g/dL) according to WHO classification of anemia [167]. Fetal anemia was confirmed when 
cord blood Hb is <12.5 g/dL [168]. 
3.7 DETECTION OF MALARIA 
Malaria was the primary outcome measure for sub-studies I, II and III and a secondary 
outcome measure for sub-study IV. We used a combination of diagnostic techniques to 
screen for malaria in order to ensure precise detection. This is because we enrolled 
pregnant women who were asymptomatic and were likely to have low densities of 
parasitemia, which may not be detected by mRDTs and microscopy with limited 
sensitivity. For sub-study I, both mRDTs and PCR was used to screening for malaria. For 
sub-studies II, III and IV we used mRDTs, microscopy, PCR and histopathology for 
malaria detection. Histopathology is a gold-standard method for screening malaria in 
placental tissue with good sensitivity. In addition, PCR has good sensitivity to detect 
parasitemia as compared to mRDTs and microscopy.  
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3.7.1 Detection of malaria by mRDT and microscopy 
We used mRDTs, which are the current standard of care for the diagnosis of malaria in 
Tanzania. Malaria RDTs (Care start, ACCESS BIO Somerset, NJ, USA) were performed 
according to the manufacturer’s instructions. Briefly, about two drops of blood were 
poured followed by wash buffer and examined after 20 minutes.  The mRDTs detect two 
parasites’ antigens namely; histidine-rich protein 2 (HRP2), specifically for P. 
falciparum, and Plasmodium lactate dehydrogenase (pLDH) an antigen marker for P. 
ovale, P. vivax, and P. malariae. Positive test was confirmed by a visible red-colored line 
which is a result of antigen-antibody complex occurring through the interaction between 
the parasites antigen in the blood sample and the monoclonal antibody on the test strip. 
On the other hand, microscopy, which is gold standard diagnostic method to screen for 
malaria parasites, was used to confirm symptomatic malaria during pregnancy and 
parasitemia at delivery for sub-studies II, III and IV. Briefly thick blood smears on 
microscopy glass slides were prepared, stained with 2% Giemsa, dried and examined with 
a 100X oil immersion objective by experienced laboratory technicians. The absence of 
asexual parasites and/or gametocytes on the thick blood smear examined at 100 high-
power fields was considered to be negative. 
3.7.2 Screening of malaria by histopathology 
Placental malaria was detected from placental tissue according to the method previously 
described [169,170]. Briefly, placenta tissue was dehydrated using Leica tissue processor 
(Leica Biosystems, Wetzlar, Germany) with ethanol at different concentrations serially, 
starting with 70%, 80%, 95%, and absolute ethanol, respectively. Then, ethanol was 
removed from the tissue specimens by xylene and embedded in paraffin wax. Microtome 
blade (Leica Biosystems, Wetzlar, Germany) was used for sectioning embedded tissue 
specimens into slides which were then stained with hematoxylin-eosin and Giemsa. Two 
slides were prepared for each placental tissue sample and read under microscopy in 
duplicate by two independent readers. Discrepant readings between the two microscopists 
were taken to an independent third reader, and conclusive results was based on two 
readers. Evidence for positive active placental malaria infection was confirmed when 
malaria parasites or parasites and pigments were observed in placental tissue. On the 
other hand, the detection of malaria pigments only in the intervillous fibrin and 
macrophages within the placental tissue was conclude as past placental malaria infection. 
3.7.3 Detection of malaria by Real-Time-PCR 
Genomic DNA was isolated from dried blood spots (DBS) using QIAamp DNA blood 
micro kit (Qiagen GmbH, Hilden, Germany) according to manufacturer’s instructions. 
We used 7500 real-time PCR system (Applied Biosystems, Foster City, CA, USA) to 
screen for Plasmodium infection (P. falciparum, P. vivax, P. ovale, and P. malariae) 
earmarking the 18S rRNA gene using a previous method [171] with minor modification as 
described previously [172]. Briefly, each specific probe for species was labeled with a 
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distinguished fluorophore, and Mustang purple was used as a passive reference dye. Each 
PCR reaction contained a final volume of 15 μL. The volume included 7.5 μL of TaqMan 
multiplex master mix (Applied Biosystems), 0.3 μL (10 μmol/L) of each species-specific 
forward primers, 0.75 μL (10 μmol/L) of the reverse primer, 0.15 μL (10 μmol/L) of each 
species-specific probe, Mustang Purple, 1.95μL DNA/RNA-free water and 3 μL sample 
DNA. We used 45 PCR cycles to analyze the samples, beginning with 95 °C for 20 s, 
followed by thermal cycles of 95 °C for 3s, and of 60 °C for 20 s. We also used negative 
and species-specific positive standard controls on each reaction plate. Optimization of the 
assay was done to ensure that all the four species are detected simultaneously. 
3.8 DNA EXTRACTION AND GENOTYPING 
We extracted genomic DNA from whole-blood samples using QIAamp DNA Midi Kit 
(Qiagen GmbH, Hilden, Germany) as instructed by the manufacturer. Then, we 
genotyped for common functional variant alleles reported to be relevant in piperaquine 
metabolism [173]. Genotyping was done according to the method previously described 
[174]. In brief, we did genotyping using TaqMan drug metabolism genotyping assay 
reagents for allelic discrimination (Applied Biosystems Genotyping Assays). The 
reagents had the following ID numbers for each SNP: C_11711730_20 for CYP3A4*1B 
(−392A>G, rs2740574), C_26201809_30 for CYP3A5*3 (c.6986A4G, rs776746), 
C_30203950_10 for CYP3A5*6 (g.14690G4A, rs10264272) and C_32287188_10 
for CYP3A5*7 (g.27131_27132insT rs41303343). For CYP2C8, ID numbers were 
C_30634034_10 for CYP2C8*2 (g.11054A>T, rs11572103), C_25625794_10 for 
CYP2C8*3 (c.416G>A, rs11572080) and C_25761568_20 for CYP2C8*4 (c.792C >G, 
rs1058930). We used 7500 Real-Time PCR system (Applied Biosystems) for genotyping. 
For each PCR reaction, the final volume was 10 μL, including 9 μl of TaqMan fast 
advanced master mix (Applied Biosystems, Waltham, MA, USA), DNA/RNA free water, 
TaqMan 20X drug metabolism genotyping assays mix (Applied Biosystems) and 1 μl 
genomic DNA. The PCR profile included an initial step at 60 °C for 30 s, hold stage at 
95 °C for 10 min and PCR stage for 40 cycles step 1 with 95 °C for 15 and step 2 with 
60 °C for 1 min and after read stage with 60 °C for 30 s. 
3.9 PHARMACOKINETICS QUANTIFICATION OF PLASMA PIPERAQUINE 
3.9.1 Materials  
The following materials and chemicals with their procurement sources were used for 
plasma piperaquine quantification. Piperaquine Tetraphosphate and Piperaquine-d6 
Tetraphosphate were purchased from Toronto Research Chemicals (Toronto, ON, 
Canada). Acetonitrile (LC/MS grade) and methanol (LC/MS grade) were purchased from 
Fisher Scientific Co. (Beerse, Belgium). Triethyl ammonia (LC/MS grade) was purchased 
from Sigma-Aldrich (Missouri, USA). Formic acid (Optima™ LC/MS grade) was 
purchased from Fisher Scientific Co. (Brno-Černovice, Czech Republic). Ultrapure water 
was produced with an ELGA Maxima system from Ninolab   (Stockholm, Sweden). 
Blank human plasma (K3EDTA added as an anticoagulant) was obtained from the 
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clinical Pharmacology laboratory at Karolinska University Hospital (Huddinge, 
Stockholm, Sweden). 
3.9.2 Piperaquine quantitation method  
We determined plasma piperaquine concentrations using Ultra high-performance liquid 
chromatography–tandem mass spectrometry (UPLC-MS/MS) method. We used a 
previously described method [175] with some minor modification. Briefly, we first 
prepared a diluent consisting of acetonitrile:water (1:9 v/v) and 0.5% formic acid. We 
used this diluet to prepare stock solutions for piperaquine reference standard and internal 
standard (piperaquine-d6). Then, we prepared standard samples for calibration (15.63, 
62.5, 250, 1000 and 10000 ng/mL) using a serial dilution method with one batch of blank 
plasma. The standard samples at 31.25, 125, and 500 ng/mL were prepared with a 
different batch of blank plasma and were used as lower, middle and high quality control 
(QC) samples, respectively.   
We used methanol (LC/MS grade) to precipitate plasma proteins. In brief, we added 50 
μL of plasma sample and 50µL of internal standard piperaquine-d6 (100ng/mL, diluted in 
acetonitrile: water at a ratio of 1:9 and 0.5% formic acid) to 300 μL of methanol. The 
solution was briefly vortex-mixed and centrifuged at 25,000g for 5min. Then, we 
carefully transferred 100μL of the supernatant to a plastic 96-well plate placed on 
autosampler and 10 μL was injected to LC-MS/MS. Piperaquine could readily adsorb to 
glass tubes due to its multiple nitrogen atoms and this may consequently affect the assay. 
Thus, we used plastic Eppendorf tubes for sample preparation.  
Furthermore, we used ACQUITY BEH C18 2.1 x 50mm, 1.8μm column (Waters, 
Milford, Massachusetts, USA) for chromatographic separation of analytes. Compounds 
were eluted with 0.1% triethyl ammonia in ultrapure water (solvent A) and 0.1% triethyl 
ammonia in acetonitrile (solvent B) at a flow rate of 0.6 mL/min. The analytes were 
eluted from the column using a linear gradient, starting at 40% solvent B (0 minute), 
isocratic hold for one minute (0-1 minute), then increased from 40% to 90% solvent B for 
two minutes (1-3 minutes), and then to 95% solvent B for 0.1 minute (3-3.1minutes), hold 
for one minute (3.1-4.1 minute), and then back to 40% solvent B (4.1-4.2 minutes). The 
total run time was 5 minutes, but the compounds were eluted after two minutes (Figure 
6).  
The analysis was set to also analyze QC samples after thirty clinical plasma samples to 
ensure the accuracy and precision of the assay. In total QC samples were run three times 
in each batch of 96 clinical samples. The limit of detection (LOD) and lower limit of 
quantification (LLOQ) were 1.5 ng/mL and 15.63 ng/mL, respectively. The validation 





Figure 6. The Liquid Chromatography Mass Spectrometry Chromatogram of piperaquine and 
piperaquine-d6 (internal standard). 
3.10 ETHICAL ASPECTS 
All the four studies included in this thesis were conducted according to ethical principles 
complied with studies involving human subjects. Before participants’ recruitment the 
protocol for all the sub-studies was reviewed and approved by the ethical review boards 
of the Muhimbili University of Health and Allied Sciences (2016- 06-07/AEC/Vol.XI/2) 
and the Tanzania National Institute for Medical Research (NIMR/HQ/R.8a/Vol.IX/2342). 
The clinical trial (Paper III) was registered with WHO-Pan African Clinical Trial 
Registry (PACTR201612001901313). All participants gave written informed consent. 
Participants who could not read and write gave thumb print signature to the consent form. 
For all sub-studies blood samples were collected for screening of malaria and hemoglobin 
concentration. For sub-study IV blood samples were collected for pharmacogenetics and 
pharmacokinetics. The procedures for blood withdraw were done according to routine 
procedures by experienced and skilled laboratory technicians to minimize harms. In 
addition, we minimized the frequency of blood withdrawal to reduce pain experience 
among participants. For example, the single blood sample taken at enrollment was used 
for malaria screening, Hemoglobin determination and the rest was stored in -80 °C freezer 
for pharmacogenetics studies. For determination of plasma piperaquine concentration, we 
used single-point sampling at day 7 which is recommended by the WHO for monitoring 
exposure of antimalarial drugs with long elimination half-life [166].  
In sub-studies II, III and IV, participants were followed until delivery. Scheduled visits 
were set according to the routine ANC visits to avoid unnecessary disturbance. 
Additionally, participants were supposed to make day-7 visits for assessment of adverse 
events and collection of blood samples for plasma piperaquine pharmacokinetics. In such 
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visits, pregnant women were compensated for their time and fare. The compensation was 
kept relatively reasonable to cover the time and fare to avoid coercion. 
For sub-studies II and III participants received study drugs. The drugs used are part of 
the public health control strategies for the prevention and treatment of malaria in 
Tanzania recommended during pregnancy from the second trimester. We included 
pregnant women on their second and third trimesters, thus, unusual adverse drug events 
were not anticipated. Pregnant women were randomized; thus, the risk and benefits were 
fairly distributed among participants. For sub-study IV, whole blood and plasma samples 
were transported to Karolinska Institutet Sweden for pharmacogenetics and 
pharmacokinetics analysis, respectively. Participants agreed with sample transfer for this 
analysis. In addition, the analysis of samples in Sweden was approved by the Stockholm 
Ethics committee (Reference number=2020-00857). To ensure participants’ 
confidentiality, all the personal information and clinical data collected were kept secret, 
and no names were used; instead, anonymous study identification numbers were used.  
3.11 DATA MANAGEMENT AND STATISTICAL ANALYSIS 
We employed experienced and trained clinicians and nurses for data collection. We used 
both paper and electronic CRF specifically created for this project (Census and Survey 
Processing system version 7, US Census Bureau, USA). To ensure quality control of 
samples, we consulted a senior laboratory scientist to assess 10% of randomly selected 
microscopy slides. In addition, we assured the quality and consistency of documentation 
whereby the PhD student cross-checked 10% of the CRF transferred from hard copies to 
the electronic CRF. 
We used descriptive statistics such as percentages, mean (one standard deviation), median 
(range) to present baselined characteristics (Papers I, II, III and IV) and malaria outcomes 
collected at delivery (Papers II, III and IV). We presented repeated malaria and anemia 
outcomes collected at ANC during pregnancy as cumulative incidence or incidence rate 
with 95% confidence interval. We used Figures and Tables to present data in all the sub-
studies. 
3.11.1 Statistical tests 
Chi square test or Fishers exact test were used to compare the prevalence of malaria and 
anemia (Papers I, II, and III). The Shapiro–Wilk test was used to assess normality of 
continous data (Papers I, II, III and IV). Hosmer and Lemeshow test was used to assess 
the goodness of model fit in logistic resgression analysis. Cohen’s kappa coefficient test 
was used to assess the agreement of methods used for screening  malaria (Papers I and II). 
An Independent t test was used to compare the mean birth weights between newborns of 
mothers who received three and above IPTp-SP versus those who received less than three 
IPTp-SP (Paper II) and between those who received IPTp-DHP versus IPTp-SP (Paper 
III). Mann-Whitney U test was used to compare mean ranks of skewed baseline data 
between the treatment groups (Paper III). We also used paired-t-test to compare log 
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Piperaquine Plasma concentration between after receiving the 1st, 2nd, and 3rd IPTp doses. 
McNemar’s test was used to compare proportions of anemia at enrollment and at delivery 
(Paper II). Poison regression model for count data was used to compare the incidence rate 
of parasitemia during pregnancy between the treatment groups (Paper III).  
3.11.2 Models of analysis  
Table 1 indicates different analysis models utilized for each individual sub-study. For 
each analysis model used, the multivariate analysis included variables with p≤ 0.2 in the 
univariate model. We used Cox Regression model to examine the predictors of 
parasitemia during pregnancy (Papers II and IV). We also used Kaplan Meir plot with 
Log Rank test to visualize graphically the significant factors associated with parasitemia 
during pregnancy overtime (Papers II and IV) as well as the risk of parasitemia during 
pregnancy over time between the treatment groups (Paper III). Logistic regression models 
were used to explore the factors associated with asymptomatic malaria and anemia (Paper 
I) and factors associated with malaria at delivery and adverse birth outcomes (Paper II 
and IV). Univariate ANOVA was used to compare mean day-7 piperaquine concentration 
between different genotypes (Paper IV). We also used Repeated measures ANOVA to 
compare between subject and within subject variations in day 7 piperaquine plasma 
concentration overtime (Paper IV). General Linear Model was used to explore factors 
associated with hemoglobin concentration (Paper I). We also used linear mixed model to 
explore factors associated with change in day-7 piperaquine concentration over time 
(Paper IV).  
In Paper III, the Intention to treat (ITT) population which included all pregnant women 
allocated to treatment groups at enrollment was used as a primary analysis (Figure 1 of 
Paper III). Additionally, per-protocol population, which included pregnant women with 
collected primary outcome (histopathological placental malaria) at delivery, was used as a 
secondary supporting analysis (Paper III). In addition, the prevalence ratio was defined as 
the prevalence of an outcome in the intervention group (IPTp-DHP) divided by the 
prevalence in the standard group (IPTp-SP). Similarly, the incidence rate ratio was 
defined as the incidence measure in the intervention group (IPTp-DHP) divided by the 
incidence measure in the standard group (IPTp-SP). Then, the differences between the 
two groups were estimated by protective efficacy (PE) defined as 1-prevalence ratio or 
1-incidence rate ratio. Furthermore, we did a secondary analysis for the outcomes 
between the two groups stratified by gravidity and excluding or including sub-patent 
parasitemia at enrollment (Paper III). 
For data analysis, we used Statistical Package for Social Sciences (SPSS) software 
version 27 (Armonk, NY: IBM Corp). Also, we used Graph Pad Prism version 8.3 for 
Windows (Graph Pad, La Jolla, CA, USA) for graphical presentations. At 95% 




Table 1: Different models of analysis used in different sub-studies  
Type of Analysis  Paper I Paper II Paper III Paper IV  
Intention to treat   ×  
Per protocol   ×  
Logistic regression  × ×  × 
GLM ×    
Univariate ANOVA    × 
Repeated measure ANOVA    × 
Kaplan Meir plot   × × × 
Cox regression   × × × 
Linear mixed model    × 




4 RESULTS AND DISCUSSION  
From January 2017 to May 2019, a total of 1,184 pregnant women were recruited. To 
determine the burden of asymptomatic malaria and anemia, a total of 819 pregnant 
women on their first ANC visit were included (Paper I). Out of 819 women, 591 met 
inclusion criteria and enrolled for sub-studies II and III. In total, 956 pregnant women 
were (1:1) randomized to receive either monthly IPTp-SP (n=478) or IPTp-DHP (n=478) 
(Paper III). 
To evaluate the effectiveness of the standard IPTp-SP, we prospectively followed 
pregnant women allocated to monthly IPTp-SP for parasitemia and anemia during 
pregnancy as well as malaria and negative birth outcomes at delivery (Paper II).  Then, 
we compared IPTp outcomes between women allocated to IPTp-DHP versus those 
allocated to IPTp-SP (Paper III). In Paper IV we prospectively followed women 
allocated to IPTp-DHP (n=446) for piperaquine pharmacogenetics, monthly day 7 
pharmacokinetics and their impact on IPTp-DHP outcomes. 
4.1 ASYMPTOMATIC PARASITEMIA, ANEMIA AND THEIR CORRELATES 
AT FIRST ANC BEFORE INITIATING IPTp (PAPER I) 
In paper I, we postulated that, several women initiating ANC might be asymptomatic but 
with parasitemia and associated anemia. In this study, we found 5.4 months as the median 
gestational age at first ANC indicating late initiation of ANC.  
4.1.1 Asymptomatic parasitemia and anemia 
We found that, 36.4% (95% CI=33.1 to 39.8; 298/819) of women had asymptomatic 
malaria associated with anemia (68.5%) at their first ANC visit.  Malaria RDT detected 
42.3% (126/298) of all asymptomatic malaria cases indicating the limited sensitivity of 
mRDT to detect asymptomatic parasitemia as compared to PCR. 
To obtain the required sample size for this sub-study (n=819), we recruited women for a 
period of one year. Thus, we observed the prevalence of asymptomatic parasitemia at 
each month persisted above 25% throughout the year (Figure 4 of Paper I).  
Our finding indicates that asymptomatic parasitemia and associated anemia at first ANC 
is common among pregnant women in Tanzania. This finding is comparable to several 
other studies conducted in sub-Saharan Africa [177-181]. Taken together, these data 
suggest that asymptomatic parasitemia during pregnancy is a public health problem that 
needs immediate attention. It may be surprising to observe such a high prevalence of 
asymptomatic parasitemia given the proved efficacy and high coverage of ITNs [35]. 
However, studies indicate the substantial change of An. arabiensis an outdoor biting 
mosquito from being rare to common [182,183]. The increase in the composition of 
outdoor biting mosquitoes may explain the observed prevalence of asymptomatic malaria. 
In addition, low utilization of ITNs could partly explain the observed finding. Outdoor 
biting mosquitoes does not only affect pregnant women but also the entire control 
 
30 
strategy for malaria, considering that key strategies in Africa (ITNs and indoor residual 
spray) mainly target indoor mosquito biting. Novel strategies especially targeting outdoor 
malaria vectors, are importantly needed. 
To estimate the burden of asymptomatic malaria accurately, we used both mRDT and 
PCR. We found nearly half of asymptomatic malaria cases as patent infection (detected 
by mRDT), suggesting a high density of parasitemia among women. This finding also 
suggests that integrating screening with mRDT and treatment of positive cases with 
efficacious drugs at first ANC would benefit pregnant women, especially primigravida 
[184]. 
Asymptomatic malaria in pregnancy may serve as a parasite reservoir contributing to 
malaria transmission cycle. This thesis did not measure gametocytemia which is an 
infective stage to mosquito. However, a study from Malawi reported that 5% of pregnant 
women at first ANC had gametocytemia, suggesting that pregnant women could 
substantially contribute to malaria transmission [185]. Furthermore, it is estimated that 
pregnant women may contribute more than 20% of malaria transmission to the public in a 
population where 90% of people have received mass drug administration for malaria 
elimination [112]. We recommend regular revising and improving the control strategies 
for malaria in pregnancy. This could benefit the efforts for malaria elimination and 
contribute to the achievement of SDG 3.3, targeting to end among others the epidemics of 
malaria infection by 2030 [186].   
4.1.2 Correlates of asymptomatic malaria and anemia  
We further examined independent correlates of asymptomatic malaria and anemia using 
logistic regression model. We found that primigravida (p=0.005) and adolescent women 
(p=0.02) had significantly higher odds of asymptomatic malaria compared to 
multigravida and adult women, respectively (Table 2 of Paper I). Equally, asymptomatic 
malaria, maternal age, gravidity and gestational age were significant predictors of anemia 
(Table 3 of Paper I).  
High burden of malaria in primigravida and adolescent women as compared to 
multigravida and adult women may be explained by parity and age-related immunity 
respectively as previously reported [187-190]. The correlation of asymptomatic malaria and 
anemia could explain the similar high burden of anemia in primigravida and adolescent 




4.2 EFFECTIVENESS OF THE STANDARD IPTp-SP FOR PREVENTION OF 
MALARIA AND ADVERSE BIRTH OUTCOMES IN PREGNANT WOMEN 
(PAPER II) 
In paper II we evaluated the effectiveness of the standard IPTp-SP to clear the observed 
sub-patent malaria (Paper I), prevent new infections and the consequent adverse birth 
outcomes among pregnant women. A cohort of 500 pregnant women was enrolled, 
administered monthly IPTp-SP and prospectively followed for IPTp outcomes till 
delivery. Baseline and follow-up characteristics are presented in Table 1 of Paper II. 
About three-quarters (256/417, 61.4%) of women received at least three doses (≥3 doses) 
of IPTp-SP which is considered as an optimal coverage. At delivery, 83% (417/500) of 
enrolled women had their primary outcome (histopathological placental malaria) 
collected (Figure 1 of Paper II).  
4.2.1 Malaria and adverse birth outcomes during pregnancy and at delivery  
To evaluate the effectiveness of IPTp-SP, we prospectively determined the incidence of 
symptomatic malaria during pregnancy, parasitemia and anemia during ANC visits. We 
also recorded adverse birth outcomes and screened for parasitemia and placental malaria 
at delivery. During the follow-up period, 2.8% (14/500) and 16% (80/500) of women 
receiving monthly IPTp-SP had symptomatic malaria and parasitemia respectively. 
Furthermore, about one fifth (20.9%, 87/417) of women had any parasitemia detected at 
delivery (Table 2 and Figure 2 of Paper II). In addition, 9.4% (39/417) of women had 
histopathological confirmed placental malaria among which 74% (29/39) was active 
placental infection (parasites) and 26% (10/39) was past infection (hemozoin pigments). 
The prevalence of malaria at delivery detected by different methods are presented in 
Table 2 of Paper II. The prevalence of composite adverse birth outcomes at delivery was 
26.5% (114/430) among which 10.9% (46/423) of women had low birth weight 
newborns. 
We found considerable burden of parasitemia during pregnancy and at delivery among 
women receiving monthly IPTp-SP. In this sub-study, we enrolled malaria-free (mRDT) 
women, thus IPTp-SP was expected to clear sub-patent malaria (not detected by mRDT 
but detected by PCR) and prevent new infection during pregnancy. However, finding one-
sixth of women with parasitemia during pregnancy and the higher proportion (74%) of 
active placental malaria could suggest the limited efficiency of IPTp-SP. The limited 
efficacy of IPTp-SP could be explained by a higher prevalence of P. falciparum 
resistance to SP in the setting [130], which might have compromised the efficacy of SP to 
clear parasitemia, placental parasites and protect women against new infection [119].  
4.2.2 Predictors of parasitemia during pregnancy, malaria and adverse birth 
outcomes at delivery  
We further explored factors associated with parasitemia during pregnancy, malaria 
outcomes at delivery and anegative birth outcomes. Primigravida women were found to 
have almost two-fold significantly higher risk of parasitemia during pregnancy compared 
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to multigravida women (Table 3 of Paper II). In addition, adolescent pregnant women 
(<20 years) had 64% significantly higher chances of having placental malaria at delivery 
as compared to adult women aged 20-34 years both on univariate (p=0.014) and 
multivariate model p=0.016 (Table 3 of Paper II). On the contrary, having parasitemia 
during pregnancy did not significantly increase the odds of any adverse birth outcome 
(OR 1.27 [95% CI= 0.75, 2.15] p = 0.38) at delivery. Similarly, taking optimal IPTp-SP 
(≥3 doses) did not reduce the odds of placental malaria (Table 3 of paper II) at delivery 
compared to lower doses (<3) of IPTp-SP. On the other hand, optimal IPTp-SP (≥3 doses) 
significantly increased the mean birth weight by 195g (95% CI= 110 to 279) p < 0.001 
and reduced the odds of low birth weight by 66% as compared to sub-optimal IPTp-SP 
(<3 doses) p=0.007. 
We could not find a significant association of parasitemia during pregnancy with adverse 
birth outcomes in this sub-study. Contrarily, previous studies reported a significant 
association between parasitemia during pregnancy with adverse birth outcomes at 
delivery [191,192]. Evidence indicate that patent parasitemia during pregnancy is 
associated with negative birth outcomes despite treatment with highly effective 
antimalarial drugs [193]. Possibly, excluding participants with patent parasitemia (detected 
by mRDT) at enrollment might be one of the reasons for the lack of significant 
association between parasitemia during pregnancy with adverse birth outcomes in the 
present sub-study. In addition, the majority of parasitemia cases during ANC visit were 
sub-patent (misses by RDT but detected by PCR). The effect of sub-patent malaria during 
pregnancy on adverse birth outcomes is controversial. A study from Benin reported a 
significant association between sub-patent malaria and adverse birth outcomes [192], 
contrary to a study from Malawi, which did not find a significant impact of sub-patent 
malaria on adverse birth outcomes [191].  
Receiving optimal (≥3 doses) IPTp-SP did not reduce the odds of placental malaria 
significantly compared to less than three doses of IPTp-SP. This data is comparable to 
other studies from endemic areas with high P. falciparum resistance to SP [104-106].  
Nevertheless, we found improved birth weight significantly associated with optimal doses 
of IPTp-SP (≥3) than lower doses of IPTp-SP (<3) consistently with previous studies 
[99,194]. The impact of IPTp-SP on birth weight is thought to be contributed by factors 
more than just the antimalarial effect of SP. For instance, the antibacterial effect of SP 
[195] is hypothesized to partly contribute to the effect of IPTp-SP on birthweight [196]. 
Although we did not control for bacterial infections, the antibacterial effect of SP might 
have partly contributed to the observed improved birth weight considering the co-
existence of malaria and bacterial infections during pregnancy in sub-Saharan Africa 
[197]. Nevertheless, this thesis reaffirms the significant impact of optimal IPTp-SP (≥ 3 
doses) in improving birth weight from a setting with moderate malaria transmission 




4.3 COMPARISON OF IPTp-DHP EFFECTIVENESS VERSUS THE 
STANDARD IPTp-SP FOR PREVENTION OF MALARIA IN PREGNANCY 
AND ADVERSE BIRTH OUTCOMES (PAPER III) 
In Paper III we compared the effectiveness of monthly IPTp-DHP versus the standard 
IPTp-SP for the prevention of malaria and negative birth outcomes. We hypothesized that 
IPTp-DHP could be superior to IPTp-SP for the prevention of malaria in pregnancy and 
negative birth outcomes in a area with moderate malaria transmission intensity. We 
enrolled a total of 956 pregnant women who were 1:1 randomized to receive either IPTp-
DHP (n=478) or the standard IPTp-SP (n=478) at each month. The distribution of 
primigravida and multigravida at baseline was not significantly different between IPTp-
SP and IPTp-DHP groups (Table 1 of Paper III). Similarly, the mean age with one 
standard deviation at enrollment was not significantly different between IPTp-SP (26.67 
years) and IPTp-DHP (26.88 years). Participants in both groups received a median of 3 
(minimum=1, maximum=5) IPTp doses.  
4.3.1 Malaria outcomes between the treatment groups  
We found significantly higher protection for both symptomatic malaria and parasitemia 
during pregnancy in IPTp-DHP group compared to IPTp-SP group. Significantly, lower 
incidence of symptomatic malaria per person-year at risk was found in IPTp-DHP (0.02) 
compared to IPTp-SP (0.12) with PE=86% (95% CI=37 to 97) p=0.002. Similarly, 
significantly lower incidence of parasitemia per person-year at risk during ANC was 
observed in IPTp-DHP (0.28) as compared to the standard IPTp-SP (0.67) with PE=59% 
(95% CI=38 to 72) p<0.001. Further analysis using Kaplan Meir plot with log Rank test 
revealed a significantly lower risk of parasitemia overtime during ANC in IPTp-DHP 
than IPTp-SP p<0.001 (Figure 2 of Paper III).  
Similarly, we found significantly lower prevalence of malaria outcomes at delivery in 
IPTp-DHP arm compared to IPTp-SP arm. The prevalence of our primary outcome 
(histopathological placental malaria) both active and past infection was significantly 
lower in IPTp-DHP (2.5%, 12/478) as compared to IPTp-SP (8.2%, 39/478) with 
PE=69% (95% CI=42 to 849) p<0.001. In our ad-hoc analysis stratified by active or past 
placental infection, IPTp-DHP was significantly associated with lower prevalence of 
active placental malaria (1.3%, 6/478) and higher PE (80%, 95% CI= 51 to 92) compared 
to the standard IPTp-SP (6.1%, 29/478) p<0.001 but not past placental malaria infection 
(Table 2 of Paper III). The presence of any malaria at delivery was significantly lower in 
IPTp-DHP (8.2%, 39/478) than in IPTp-SP (18.2%, 87/478) with PE=55 (95% CI=36 to 
71) p<0.001. Similarly, we found significantly lower prevalence of parasitemia in 
placental blood, cord blood and maternal peripheral blood by RDT, microscopy and PCR 
in IPTp-DHP arm as compared to IPTp-SP arm (Table 2 of Paper III). 
This thesis reports the superiority of monthly IPTp-DHP to IPTp-SP for the prevention of 
malaria in pregnancy from an area of moderate of malaria transmission intensity for the 
first time. We confirm that IPTp-DHP initiated either on the second or third trimester is 
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superior to IPTp-SP for the prevention of malaria in pregnancy. Our finding is 
comparable to previous trials which reported the superiority of IPTp-DHP to IPTp-SP for 
prevention of malaria in pregnancy when initiated early during the second trimester (≤ 20 
weeks) [114,144] or second and third trimesters [113] but in areas with high malaria 
transmission intensity. Interpretation of these findings together, suggest that monthly 
IPTp-DHP may be suitable regimen to replace IPTp-SP in areas with high prevalence of 
P. falciparum resistance to SP.  
4.3.2 Adverse birth outcomes between the treatment groups  
We were interested in examining whether the superior effects of IPTp-DHP to IPTp-SP 
on malaria outcomes could be translated to a superior impact on anemia during pregnancy 
and negative birth outcomes. Using ITT analysis, we report a significantly lower 
prevalence of LBW (p=0.003) and higher mean birth weight (mean difference=55, 95% 
CI= 19 to 93g; p=0.004) associated with IPTp-DHP compared to IPTp-SP. However, we 
did not find a significant difference in anemia during pregnancy and composite adverse 
birth outcome (stillbirth, premature birth, spontaneous abortion, LBW and fetal anemia) 
between IPTp-DHP and IPTp-SP groups (Table 3 of Paper III).  
The association between malaria in pregnancy with LBW is well established [198]. Thus, 
it may not be surprising to observe the superior effect of IPTp-DHP on malaria in 
pregnancy being translated to a superior effect on birth weight as compared to IPTp-SP. 
However, this finding contradicts previous trials [113,114,144]. Possibly, the differences in 
the design and the intensity of malaria transmission between the different settings could 
partly account for the observed difference of IPTp-DHP on LBW as compared to the 
standard IPTp-SP. Essentially, this thesis adds an evidence to the growing literature, for 
the first time showing the superiority of IPTp-DHP against LBW as compared to IPTp-SP 
from a moderate malaria transmission setting.   
Furthermore, the lack of IPTp-DHP significant impact on anemia as compared to IPTp-
SP in this thesis contradicts previous trials [113,114,144]. One reason to account for the 
observed difference might be the exclusion of women with patent malaria (detected by 
mRDT) at enrollment in our design.  The association of patent malaria with anemia is 
well known. Therefore, excluding women with patent malaria in our design might have 
limited the impact of IPTp-DHP on malaria-associated anemia. Also, differences in other 
causes of anemia in different geographical settings might have partly contributed to the 
observed difference.  
4.3.3 Implication of the findings to the Sustainable Development Goal number 3  
The need for the superior drug for IPTp is inevitable considering the adverse effects of 
pregnancy-associated malaria in utero and beyond uterine life. Recent evidence indicates 
that placental malaria is associated with a significantly higher risk of malaria [199] and 
non-malaria infections during infancy and childhood [200]. The possible mechanism for 
this association could be the fetal immune tolerance caused by regulatory T cells when 
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exposed to malaria antigens in utero persisting to infancy and childhood [76]. Both 
malaria and non-malaria infections are the most common causes of infant and child 
mortality in sub-Saharan Africa [201-203]. Therefore, our findings suggest that monthly 
IPTp-DHP will not only reduce malaria in pregnancy and associated LBW but also could 
contribute to the achievement of global SDG number 3.2, targeting to end deaths that 




4.4 PHARMACOGENETICS AND PHARMACOKINETICS OF PIPERAQUINE 
AND THEIR RELEVANCE ON TREATMENT OUTCOMES DURING IPTp 
WITH DHP (PAPER IV) 
In Paper IV we investigated the pharmacogenetics, day-7 pharmacokinetics of 
piperaquine and their association with treatment outcomes during IPTp with DHP. Our 
hypothesis was based on the fact that IPTp-DHP did not completely eliminate parasitemia 
during pregnancy (Paper III). We then postulated that the observed parasitemia in IPTp-
DHP group would possibly be contributed by inter-individual variations in plasma 
piperaquine concentration associated with both genetic and non-genetic variations. We 
prospectively followed pregnant women (n=446) who received monthly IPTp-DHP in a 
two arm randomized clinical trial (sub-study III). From these women, we collected 
samples for piperaquine pharmacogenetics and followed them for day-7 pharmacokinetics 
after each monthly IPTp-DHP dose, malaria and negative birth outcomes till delivery. 
The baseline characteristics are summarized in Table 1 of Paper IV. 
4.4.1 Day-7 piperaquine pharmacokinetics, pharmacogenetics and their 
associations with IPTp-DHP outcomes 
We observed that the repeated administration of IPTp-DHP at each month caused a 
significant increase in plasma day-7 piperaquine concentration over time. Using paired t-
test, we found significantly lower geometric mean day-7 piperaquine concentration after 
receiving the first IPTp-DHP compared to geometric mean day-7 piperaquine plasma 
concentration after receiving the second IPTp-DHP dose (p<0.001). Similarly, the day 7 
piperaquine geometric mean difference between after receiving the second and the third 
IPTp-DHP doses was significantly different being higher after receiving the third IPTp-
DHP dose (Figure 1 of Paper IV). We also noticed that few women had day-7 piperaquine 
concentration below the threshold (30ng/mL) established for treatment success after the 
first (6.1%, 15/245), second (4.1%, 5/122) and third (3.6%, 2/55) IPTp-DHP doses.  
We presented our results for the observed genotypes and allele frequency in Table 3 of 
Paper IV. We did not detect CYP2C8*3 allele in our study population from Tanzania. In 
this population, all observed allele frequencies were in agreement with Hardy-Weinberg 
equilibrium (Table 3 of Paper IV). 
The observed significant increase in mean day-7 concentration of piperaquine associated 
with repeated IPTp-DHP given monthly is comparable to previous IPTp studies which 
reported a significant increase in piperaquine trough plasma concentration over time 
during monthly IPTp with DHP [158,159]. As a limitation to this sub-study, overall 
piperaquine exposure was not assessed. However, a recent study reported that the 
predicted peak plasma concentration of piperaquine was not altered significantly despite 
the significant increase in plasma trough concentration with repeated IPTp-DHP [159]. 
This may suggest that the significant accumulation of plasma piperaquine with repeated 
IPTp-DHP could be safe but providing optimum protection against malaria and associated 
LBW. In addition, the high percent of women who attained optimum day-7 piperaquine 
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concentration (≥30ng/mL) further support that IPTp-DHP given monthly could provide 
optimal plasma piperaquine concentration needed for sufficient malaria protection in 
more than ninty percent of women. 
We then explored the impact of pharmacogenetic variations, piperaquine day-7 
pharmacokinetics and baseline characteristics on parasitemia during pregnancy and 
malaria and adverse birth outcomes at delivery. Using Cox regression model, we 
observed significantly higher risk of parasitemia at ANC overtime during pregnancy 
(HR= 5.22 95% CI=1.70 to 16) in pregnant women with lower (<30ng/mL) day-7 
piperaquine concentration when compared to women who attained concentration 
≥30ng/mL after receiving the first IPTp-DH dose (p=0.004). We also observed a similar 
non-significant trend after the second IPTp-DHP dose (HR= 4.40 95% CI=0.94 to 20) 
p=0.05. We examined this association graphically on Kaplan Meir plot with Log Rank 
test. In this analysis, the risk of parasitemia during ANC overtime was abserved to be 
significantly higher in women with lower day 7 piperaquine concentration (<30ng/mL) 
compared to those with higher concentration (≥ 30ng/mL) both after the first (Log Rank 
p=0.002) and the second (Log Rank p=0.02) IPTp-DHP doses (Figure 4 of paper IV).  
On the contrary, we did not find significant association between genetic variation in 
CYP3A4*1B, CYP3A5, and CYP2C8, and baseline characteristics with risk of parasitemia 
during pregnancy (Table 6 of Paper IV). Equally, baseline characteristics and 
CYP3A4*1B, CYP3A5 and CYP2C8 genotypes were not significantly associated with any 
parasitemia and adverse birth outcomes at delivery.  
This thesis report for the first time the association between piperaquine pharmacogenetics 
and day-7 pharmacokinetics with treatment outcomes during IPTp with DHP. The 
observed significantly higher risk of parasitemia associated with lower day 7 piperaquine 
concentration is comparable to previous studies which reported the association of lower 
day-7 piperaquine concentration with treatment failure in treatment regimen [204-206]. Our 
result implies that the pre-established target day-7 piperaquine concentration (30ng/ml) 
[159] for the treatment regimen could also be used for DHP surveillance in IPTp regimen.  
4.4.2 Predictors of day-7 piperaquine pharmacokinetics 
We examined the impact of pharmacogenetics variations and baseline characteristic on 
day-7 piperaquine pharmacokinetics. We found significantly lower geometric mean day 7 
piperaquine concentration in women with defective CYP2C8 allele compared to women 
with CYP2C8*1/*1 genotype after the second IPTp-DHP dose (Figure 2 and Table 4 of 
Paper IV). Also, we observed a similar non-significant trend after the first IPTp-DHP 
dose p=0.27 (Figure 2 of Paper IV). Using linear mixed model, we found 5% non-
significant lower change in log day 7 piperaquine concentration in women with at least 
one defective CYP2C8 (*2 or *4) allele compared to wild type p= 0.11 (Table 5 of paper 
IV). We did not observe a significant association between day-7 piperaquine 
concentration with genetic variations in CYP3A4*1B and CYP3A5 (Table 4 of paper IV).  
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Using linear mixed model, we observed a significant association between primigravida 
and lower change in monthly day-7 piperaquine concentration as compared to 
multigravida p=0.04 (Table 5 of Paper IV). Bodyweight and trimester at enrollment were 
not associated with a significant effect on change in day-7 piperaquine concentration 
(Table 5 of Paper IV). 
Data in the literatures regarding the pharmacogenetics-pharmacokinetics relationship for 
CYP2C8*2 which is predominantly found in black population are largely unavailable 
contrary to data regarding CYP2C8*3 found in white population [207-213]. Current 
evidence concerning in vivo effects of CYP2C8*3 genotype are disagreeing with each 
other. Some studies reported significantly lower plasma concentration indicating 
increased metabolism of drugs [210,213-215] while others reported higher plasma 
concentration suggesting reduced metabolism [208,211,212] associated with defective 
CYP2C8*3 alleles as compared to the wild type. It is hypothesized that the activity of 
CYP2C8 alleles could be substrate-specific. 
In this thesis, significant association between day-7 piperaquine plasma concentration 
with CYP2C8 genotypes was found from a population with dominant CYP2C8*2 allele. 
We observed lower day-7 piperaquine concentration in women with at least one defective 
CYP2C8 allele after the first and second monthly doses of IPTp-DHP than in 
homozygotes wild type. The association was significant after the second IPTp-DHP dose 
with lower concentration in women with CYP2C8*2/*2 genotype compared to those the 
wild type genotype. Notably, our exploration on the trend of plasma piperaquine 
concentration change with repeated monthly IPTp-DHP doses revealed significantly 
higher increase in participants with CYP2C8*2/*2 genotype than in participants with one 
defective CYP2C8 (*2 or*4) allele and CYP2C8*1/*1 genotype (Figure 3 of Paper IV). 
The accumulation of plasma piperaquine concentration with repeated monthly IPTp-DHP 
and pregnancy-associated alterations in expression of CYP enzymes could modify the 
metabolic activity in CYP2C8 genotype. This thesis identified the potential impact of 
CYP2C8 genotypes on the pharmacokinetics of piperaquine during IPTp which warrant 
further studies for more evidence.  
This thesis did not find significant impact associated with CYP3A4*1B and CYP3A5 
genetic variations on day-7 piperaquine pharmacokinetics. Our result is comparable to 
one study which reported a similar non-significant association between CYP3A4*1B and 
CYP3A5*3 genotypes with piperaquine pharmacokinetics from Cambodia [162]. This 
finding suggests that monitoring of CYP3A4*1B and CYP3A5 pharmacogenetics may not 




5 CONCLUSIONS AND PERSPECTIVES  
5.1 CONCLUSIONS  
This thesis evaluated the effectiveness of IPTp for the prevention of malaria and negative 
birth outcomes in a setting with high parasite resistance to SP and moderate malaria 
transmission intensity. Here, I describe my contribution to the growing evidence 
indicating the significant impact of IPTp-DHP on malaria in pregnancy and LBW as 
compared to the standard IPTp-SP.  
Firstly, we reported that asymptomatic parasitemia and associated anemia is common at 
the first ANC before initiating IPTp. We also observed higher burden of asymptomatic 
malaria and anemia in primigravida and adolescent pregnant women, similar to other 
findings in sub-Sahara Africa.  
Moreover, we observed substantial rates of parasitemia, placental malaria and associated 
adverse birth outcomes in pregnant women receiving the standard monthly IPTp-SP. We 
found that receiving optimal IPTp-SP did not prevent placental malaria but improved 
birth weight compared to lower IPTp-SP doses. 
In addition, we reported the superiority of monthly IPTp-DHP to IPTp-SP for the 
prevention of malaria in pregnancy in areas with moderate malaria transmission intensity, 
similar to the findings from areas with high malaria transmission intensity. Also, we 
found for the first time, the superiority of IPTp-DHP on malaria translated to superior 
effects on LBW as compared to IPTp-SP. The current data taken together with the 
previous findings support the hypothesis that monthly IPTp-DHP could replace IPTp-SP 
in areas with high P. falciparum resistance to SP.  
Finally, we reported for the first time, the association of lower day-7 piperaquine 
concentration with the risk of parasitemia during pregnancy. We also identified the 
potential impact of CYP2C8 genotypes on piperaquine pharmacokinetics.  
5.2 FUTURE PERSPECTIVES  
Although my PhD thesis has responded to several research questions, some other areas in 
this field require further investigation.  
 For instance, we observed more than half of asymptomatic parasitemia as sub-
patent infection (not detected by RDT but detected by PCR). Currently, the impact 
of sub-patent malaria on adverse birth outcomes are inconclusive. It would be nice 
to further investigate the effect of sub-patent parasitemia on adverse birth outcomes 
to give more evidence. This will inform policymakers and help to improve the 
control of malaria in pregnancy. A systematic review and meta analysis on the 
available few literatures could give a clue. Moreover, it would be interesting to 
quantify the role of asymptomatic malaria in pregnant women on the overall malaria 
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transmission, especially in areas targeting elimination. This would help to revise 
and improve elimination strategies.  
 Additionally, we observed that optimal IPTp-SP did not prevent placental malaria 
but improved birth weight as compared to sub-optimal IPTp-SP. The antibacterial 
effect of SP has previously been hypothesized to partly contribute for the observed 
improved birth weight [195]. However, the exact mechanism is not yet known. It 
would then be interesting to scrutinize the exact mechanism and describe why lower 
doses (<3) of IPTp-SP would not be associated with improved birth weight.  
 Furthermore, we found that IPTp-DHP is superior to IPTp-SP for the prevention of 
malaria and LBW. It would be important to further investigate the feasibility and 
adherence of IPTp-DHP. This will help policy decisions for IPTp especially in areas 
with high SP resistance. 
 We also found that IPTp-DHP was not superior to IPTP-SP on composite adverse 
birth outcomes. However, in sub-Sahara Africa adverse birth outcomes could also 
be associated by infections other than malaria [216]. Considering the reported 
antibacterial effect of SP, it would be interesting to investigate whether combining 
monthly IPTp-DHP with SP would be superior to IPTp-DHP alone or IPTp-SP for 
prevention of composite adverse birth outcomes. 
 In this thesis, we reported the superiority of IPTp-DHP to IPTp-SP among pregnant 
women on their second and third trimesters who are currently eligible for IPTp. 
However, pregnant women on their first trimester have similar risks of malaria and 
associated negative birth outcomes. Recent evidence indicates that artemisinin-
based combination therapy is safe during the first trimester [217]. It would then be 
interesting to explore the safety and efficacy of IPTp-DHP during the first trimester.  
 We have also found a significant association between lower day 7-piperaquine 
concentration (<30ng/mL) with a higher risk of parasitemia, indicating that this 
target concentration could be a predictor of IPTp-DHP effectiveness. However, this 
thesis reported data from an area with no reported emerging DHP resistance [218]. 
Thus, it will be interesting to investigate if this target concentration could also be 
applied to areas where reduced parasite sensitivity due to emerging DHP resistance 
was reported [219,220].  
 In this thesis, we identified for the first time a significant association between 
CYP2C8 genotypes with piperaquine pharmacokinetics. It would be interesting to 
further explore the impact of CYP2C8 on piperaquine pharmacokinetics and clinical 
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